Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
NCT ID: NCT01273896
Last Updated: 2015-11-20
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
22 participants
INTERVENTIONAL
2011-01-31
2013-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
STA-9090 is an experimental drug that works by breaking down cancer proteins. When the cancer proteins are destroyed, the cancer cells die. STA-9090 is an experimental drug that is not yet approved for the treatment of cancer by the United States (FDA) Food and Drug Administration . STA-9090 has been tested in cancer patients in other trials and a safe dose for this drug has been found. We are now interested to see how active this drug is against breast cancer.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
STA-9090
This will be a monotherapy, open-label phase 2 study of STA-9090 in patients who have metastatic breast cancer.
STA-9090
All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecutive weeks followed by a 1 week dose-free interval. Subjects tolerating therapy may continue on study until disease progression.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
STA-9090
All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecutive weeks followed by a 1 week dose-free interval. Subjects tolerating therapy may continue on study until disease progression.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pathologically confirmed diagnosis of breast cancer
* Metastatic or advanced stage breast cancer
* Prior treatment with at least one and no more than three lines of biologic and/or chemotherapy for metastatic breast cancer (excluding hormonal therapy)
* Patients with HER2+ disease must have received prior treatment with Trastuzumab
* Patients with ER and/or PR+ disease must have received prior treatment with hormonal therapy
* Off cytotoxic chemotherapy or biologic therapy (excluding Hormonal therapy) ≥ 3 weeks
* Measurable disease by RECIST 1.1
* Central nervous system metastases are permitted if treated and radiographically and clinically stable for at least 4 weeks prior to first dose of STA-9090
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
* Life expectancy of at least 3 months
* Adequate hematologic function as defined by:
* Absolute neutrophil count ≥1,500 cells/μL
* Platelets ≥100,000/μL
* Hemoglobin ≥ 9.0g/dL
* Adequate hepatic function as defined by:
* Serum bilirubin ≤ 1.5 X upper limit of normal (ULN);
* Adequate renal function as defined by a serum creatinine ≤ 1.5 x ULN
* AST, ALT, and alkaline phosphatase ≤ 3 × ULN except for:
* Patients with hepatic metastases: ALT and AST ≤ 5 × ULN
* Patients with hepatic and/or bone metastases: alkaline phosphatase ≤ 5 × ULN
* Patients with Gilbert's disease: serum bilirubin \< 5 mg/dL
* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
* Female subjects of childbearing potential and males must agree to use adequate contraception (e.g., hormonal or barrier method of birth control; abstinence) for the duration of study treatment
* Female subjects of childbearing age must have a negative serum pregnancy test at study entry.
Exclusion Criteria
* Major surgery within 4 weeks prior to first dose of STA-9090
* Poor peripheral venous access for study drug administration. Study drug administration via indwelling catheters allowed only if the catheter is made of silicone material.
* History of severe (grade 3 or 4) allergic or hypersensitivity reactions to excipients (e.g., Polyethylene glycol \[PEG\] 300 and Polysorbate 80)
* Baseline QTc \> 470 msec
* Ventricular ejection fraction (EF) \<50% at baseline
* Treatment with chronic immunosuppressants (e.g., cyclosporine following transplantation)
* Women who are pregnant or lactating
* Uncontrolled intercurrent illness including, but not limited to, human immunodeficiency virus (HIV)-positive subjects receiving combination antiretroviral therapy, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, ventricular arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Other medications, or severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results in the judgment of the investigator
* Seizure disorder or requirement for seizure medication
* Prior treatment with an HSP90 inhibitor
* persistent adverse events of prior therapies that are \> 1 grade 1 in severity
* history of or current coronary artery disease, myocardial infarction, angina pectoris, angioplasty or coronary bypass surgery
* history of or current uncontrolled dysrhythmias, or requirement for antiarrhythmic medications, or Grade 2 or greater left bundle branch block
* New York Heart Association class II/III/IV congestive heart failure with a history of dyspnea, orthopnea, or edema that requires current treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, beta blockers or diuretics
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Synta Pharmaceuticals Corp.
INDUSTRY
Memorial Sloan Kettering Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shanu Modi, MD
Role: PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Memorial Sloan-Kettering at Basking Ridge
Basking Ridge, New Jersey, United States
Memorial Sloan-Kettering Cancer Center at Commack
Commack, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Memorial Sloan-Kettering Cancer Center at Mercy Medical Center
Rockville Centre, New York, United States
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
Sleepy Hollow, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Memorial Sloan-Kettering Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10-145
Identifier Type: -
Identifier Source: org_study_id